Want to see HK:1061 full AI Analyst Report?
Essex Bio-Technology (1061) Ratios
Essex Bio-Technology Ratios
HK:1061's free cash flow for Q2 2026 was $73.49M. For the 2026 fiscal year, HK:1061's free cash flow was decreased by $-27.63M and operating cash flow was $101.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.11 | 1.81 | 1.54 | 2.16 | 2.24 |
| Quick Ratio | 2.01 | 1.73 | 1.46 | 2.02 | 2.10 |
| Cash Ratio | 1.02 | 0.79 | 0.63 | 0.97 | 0.97 |
| Solvency Ratio | 0.35 | 0.41 | 0.37 | 0.27 | 0.34 |
| Operating Cash Flow Ratio | 0.40 | 0.52 | 0.42 | 0.68 | 0.59 |
| Short-Term Operating Cash Flow Coverage | 4.71 | 5.28 | 1.44 | 3.64 | 2.67 |
| Net Current Asset Value | $ 542.45M | $ 423.98M | $ 341.50M | $ 232.95M | $ 418.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.06 | 0.10 | 0.18 | 0.20 |
| Debt-to-Equity Ratio | 0.14 | 0.09 | 0.15 | 0.28 | 0.33 |
| Debt-to-Capital Ratio | 0.13 | 0.08 | 0.13 | 0.22 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.04 | 0.02 | 0.18 | 0.19 |
| Financial Leverage Ratio | 1.45 | 1.40 | 1.47 | 1.57 | 1.65 |
| Debt Service Coverage Ratio | 5.26 | 4.38 | 1.41 | 2.39 | 2.39 |
| Interest Coverage Ratio | 47.06 | 52.69 | 27.68 | 23.79 | 43.70 |
| Debt to Market Cap | 0.15 | 0.10 | 0.19 | 0.20 | 0.20 |
| Interest Debt Per Share | 0.63 | 0.34 | 0.54 | 0.87 | 1.00 |
| Net Debt to EBITDA | -0.91 | -0.92 | -0.52 | -0.17 | -0.24 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.20% | 89.75% | 90.20% | 90.26% | 85.23% |
| EBIT Margin | 22.98% | 21.25% | 21.03% | 20.64% | 24.65% |
| EBITDA Margin | 26.43% | 24.00% | 24.52% | 23.79% | 26.66% |
| Operating Profit Margin | 20.28% | 19.21% | 18.18% | 20.72% | 24.62% |
| Pretax Profit Margin | 22.86% | 22.49% | 20.28% | 19.76% | 24.09% |
| Net Profit Margin | 17.54% | 18.40% | 16.13% | 17.11% | 21.13% |
| Continuous Operations Profit Margin | 17.54% | 18.40% | 16.13% | 17.12% | 21.13% |
| Net Income Per EBT | 76.71% | 81.82% | 79.55% | 86.58% | 87.71% |
| EBT Per EBIT | 112.74% | 117.08% | 111.50% | 95.37% | 97.84% |
| Return on Assets (ROA) | 9.11% | 10.30% | 9.73% | 8.31% | 12.08% |
| Return on Equity (ROE) | 13.18% | 14.47% | 14.31% | 13.02% | 19.95% |
| Return on Capital Employed (ROCE) | 13.50% | 14.10% | 15.39% | 12.69% | 18.55% |
| Return on Invested Capital (ROIC) | 10.10% | 11.18% | 10.95% | 10.46% | 15.18% |
| Return on Tangible Assets | 14.67% | 15.03% | 16.17% | 13.57% | 17.13% |
| Earnings Yield | 14.88% | 18.41% | 19.70% | 9.35% | 12.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.56 | 2.71 | 2.68 | 2.64 | 2.29 |
| Payables Turnover | 16.94 | 23.26 | 15.81 | 12.05 | 54.17 |
| Inventory Turnover | 2.47 | 2.90 | 2.66 | 1.53 | 2.48 |
| Fixed Asset Turnover | 3.51 | 4.03 | 4.10 | 3.29 | 4.65 |
| Asset Turnover | 0.52 | 0.56 | 0.60 | 0.49 | 0.57 |
| Working Capital Turnover Ratio | 2.54 | 3.31 | 3.14 | 1.74 | 2.07 |
| Cash Conversion Cycle | 268.77 | 244.87 | 250.29 | 346.06 | 299.68 |
| Days of Sales Outstanding | 142.40 | 134.87 | 136.29 | 138.51 | 159.19 |
| Days of Inventory Outstanding | 147.92 | 125.69 | 137.09 | 237.85 | 147.23 |
| Days of Payables Outstanding | 21.54 | 15.69 | 23.09 | 30.30 | 6.74 |
| Operating Cycle | 290.32 | 260.56 | 273.38 | 376.36 | 306.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.54 | 0.65 | 0.59 | 0.67 | 0.71 |
| Free Cash Flow Per Share | 0.23 | 0.57 | 0.37 | 0.17 | 0.29 |
| Dividend Paid and CapEx Coverage Ratio | 1.23 | 3.54 | 2.02 | 1.13 | 1.38 |
| Capital Expenditure Coverage Ratio | 1.75 | 8.30 | 2.65 | 1.35 | 1.67 |
| Operating Cash Flow Coverage Ratio | 0.88 | 1.97 | 1.15 | 0.78 | 0.72 |
| Operating Cash Flow to Sales Ratio | 0.17 | 0.22 | 0.20 | 0.29 | 0.25 |
| Free Cash Flow Yield | 6.16% | 19.42% | 15.12% | 4.14% | 5.77% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.73 | 5.43 | 5.08 | 10.69 | 8.25 |
| Price-to-Sales (P/S) Ratio | 1.18 | 1.00 | 0.82 | 1.83 | 1.74 |
| Price-to-Book (P/B) Ratio | 0.89 | 0.79 | 0.73 | 1.39 | 1.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 16.23 | 5.15 | 6.62 | 24.14 | 17.34 |
| Price-to-Operating Cash Flow Ratio | 6.98 | 4.53 | 4.12 | 6.30 | 6.98 |
| Price-to-Earnings Growth (PEG) Ratio | 1.82 | 0.53 | 0.20 | -0.31 | 0.14 |
| Enterprise Value Multiple | 3.55 | 3.24 | 2.82 | 7.52 | 6.29 |
| Enterprise Value | 1.70B | 1.30B | 1.18B | 2.36B | 2.75B |
| EV to EBITDA | 3.55 | 3.24 | 2.82 | 7.52 | 6.29 |
| EV to Sales | 0.94 | 0.78 | 0.69 | 1.79 | 1.68 |
| EV to Free Cash Flow | 12.92 | 4.01 | 5.59 | 23.60 | 16.69 |
| EV to Operating Cash Flow | 5.56 | 3.52 | 3.48 | 6.16 | 6.72 |
| Tangible Book Value Per Share | 1.92 | 2.09 | 1.82 | 1.19 | 1.55 |
| Shareholders’ Equity Per Share | 4.26 | 3.74 | 3.37 | 3.02 | 3.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.18 | 0.20 | 0.13 | 0.12 |
| Revenue Per Share | 3.20 | 2.94 | 2.99 | 2.30 | 2.84 |
| Net Income Per Share | 0.56 | 0.54 | 0.48 | 0.39 | 0.60 |
| Tax Burden | 0.77 | 0.82 | 0.80 | 0.87 | 0.88 |
| Interest Burden | 0.99 | 1.06 | 0.96 | 0.96 | 0.98 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 |
| SG&A to Revenue | 0.67 | 0.69 | 0.13 | 0.12 | 0.09 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.74 | 1.20 | 1.23 | 1.47 | 1.04 |
Currency in HKD